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Bi-allelic Variants in METTL5 Cause
Autosomal-Recessive Intellectual Disability
and Microcephaly
Elodie M. Richard,1,14 Daniel L. Polla,2,3,14 Muhammad Zaman Assir,4,5,6 Minerva Contreras,7
Mohsin Shahzad,4,6 Asma A. Khan,8 Attia Razzaq,2,8 Javed Akram,4,6,9 Moazzam N. Tarar,6
Thomas A. Blanpied,7 Zubair M. Ahmed,1 Rami Abou Jamra,10,11 Dagmar Wieczorek,12,13
Hans van Bokhoven,2 Sheikh Riazuddin,4,6,8,* and Saima Riazuddin1,*
Intellectual disability (ID) is a genetically and clinically heterogeneous disorder, characterized by limited cognitive abilities and impaired
adaptive behaviors. In recent years, exome sequencing (ES) has been instrumental in deciphering the genetic etiology of ID. Here,
through ES of a large cohort of individuals with ID, we identified two bi-allelic frameshift variants in METTL5, c.344_345delGA
(p.Arg115Asnfs*19) and c.571_572delAA (p.Lys191Valfs*10), in families of Pakistani and Yemenite origin. Both of these variants were
segregating with moderate to severe ID, microcephaly, and various facial dysmorphisms, in an autosomal-recessive fashion. METTL5
is a member of the methyltransferase-like protein family, which encompasses proteins with a seven-beta-strand methyltransferase
domain. We found METTL5 expression in various substructures of rodent and human brains and METTL5 protein to be enriched in
the nucleus and synapses of the hippocampal neurons. Functional studies of these truncating variants in transiently transfected orthol-
ogous cells and cultured hippocampal rat neurons revealed no effect on the localization of METTL5 but alter its level of expression. Our
in silico analysis and 3D modeling simulation predict disruption of METTL5 function by both variants. Finally, mettl5 knockdown in
zebrafish resulted in microcephaly, recapitulating the human phenotype. This study provides evidence that biallelic variants inMETTL5
cause ID and microcephaly in humans and highlights the essential role of METTL5 in brain development and neuronal function.
Intellectual disability (ID) is characterized by significant
impairment in cognitive ability and adaptive behaviors,
with a disease onset generally before adulthood.1 With a
prevalence of 1%–2% worldwide,2,3 ID is a complex group
of disorders that has high phenotypic variability as well as
heterogeneous etiology, encompassing genetic and envi-
ronmental factors.4 Autosomal-recessive ID (ARID) is esti-
mated to account for more than 50% of genetic causes of
ID.4 The identification of novel ARID genes has gained
momentum in recent years through implementation
of contemporary high-throughput sequencing technolo-
gies (e.g., exome sequencing) and study of large consan-
guineous families.5–12 However, these molecular studies
highlight extreme genetic heterogeneity with an estimate
of more than 2,500 genes associated with various
forms of ID.13
Here, we illustrate the integration of two large-scale
studies, GENCODYS6 and CARID,9 and subsequent func-
tional analyses to identify variants that affect function in
METTL5, segregating with ID, microcephaly, and facial
dysmorphisms in two large families of Pakistani and
Yemenite origin.Written informed consents were obtained
for all individuals involved. This study adhered to the
World Health Association Declaration of Helsinki (2013)
and was approved by the Institutional Review Board at
University of Maryland School of Medicine, Baltimore,
USA, Center of Excellence in Molecular Biology (CEMB),
University of the Punjab, Lahore, Pakistan, the Institu-
tional Review Board Commissie Mensgebonden Onder-
zoek Regio Arnhem-Nijmegen, the Netherlands, and an
ethical votum for MRNET in Erlangen, Germany. Medical
and family history, developmental childhood milestones,
anthropometric measurements, and findings of physical
examination were collected and detailed clinical pheno-
types were described with Human Phenotype Ontology
(HPO) terms.14 Venous blood samples were collected
from research participants for DNA extraction.
Family 1 (PKMR43M; Figure 1A; Table 1) was enrolled
from Dargai, Malakand Agency in Khyber Pakhtoon
Khawa province of Pakistan. There are five individuals pre-
senting with severe ID (HP:0010864), of which two were
deceased at the time of assessment. The age of affected
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individuals at the time of evaluation ranged from 14 to
31 years, but the ID was already apparent in early child-
hood. All three affected individuals had significant delay
in childhood milestones including verbal, fine motor,
and social skills. There was no history of epilepsy. The
apparent behavioral and physical abnormalities noticed
in the affected individuals included attention deficit
hyperactivity disorder (ADHD) (HP:0007018), aggressive
behavior (HP:0000718), microcephaly (HP:0000252),
muscular hypotonia (HP:0001252), overhanging nasal
tip (HP:0011833), wide nasal base (HP:0012810), and
abnormality of dental morphology (HP:0006482)
(Figure 1B; Table 1). The affected female had short stature
(HP:0004322) and decreased body weight (HP:0004322),
i.e., height and weight below 3rd percentile for her age
and gender. Evaluation of motor system was unremarkable
and gait was normal in all affected individuals with no
apparent hearing or vision loss (Table 1). Magnetic reso-
nance imaging (MRI) of the individual II:2 confirmed the
measured microcephaly and did not reveal any degenera-
tion of brain tissue (Figure S1).
Family 2 (F47949; Figure 1A; Table 1) had Yemenite
origin and was enrolled and evaluated in Germany at the
Institutes of Human Genetics in Essen and Du¨sseldorf.
Two affected male individuals were 7 and 12 years old at
the time of enrollment and clinical evaluation. Birth his-
tory was significant for fetal tachycardia and non-immune
hydrops fetalis (HP:0001790) in affected individual III:3,
while secundum atrial septal defect (HP:0001684) and pul-
monic stenosis (HP:0004415) was observed in affected in-
dividual III-2. One affected individual presented severe
ID (HP:0010864) and the other one moderate to severe
Figure 1. Homozygous Frameshift Vari-
ants in METTL5 Lead to Intellectual
Disabilities Associated with Dysmorphic
Features
(A) Pedigrees of Pakistani family
PKMR43M and Yemenite family F47949
segregating intellectual disabilities and
microcephaly due to different frameshift
deletions in METTL5, c.344_345delGA
and c.571_572delAA, respectively. The
filled symbols represent affected individ-
uals and a double horizontal line connect-
ing parents represents a consanguineous
marriage.
(B) Facial appearance of affected individ-
uals. All affected individuals have micro-
cephaly. Various facial dysmorphisms
were reported such as large ear shape
(PKMR43M II:1, F47949 III:2), dental
anomalies (PKMR43M II:3), and large
nose (F47949 III:2).
ID (HP:0002342). Both affected indi-
viduals had delayed childhood mile-
stones, self-mutilating behavior
(HP:0000742), and autism spectrum
disorder (HP:0000729). There was no
history of epilepsy or motor weakness. Physical examina-
tion was significant for microcephaly (HP:0000252), short
stature (HP:0004322), low body weight (HP:0004325),
wide nasal base (HP:0012810), large nose with broad nasal
tip (HP:0000455), low-set and posteriorly rotated ears, and
truncal ataxia (HP:0002078) (Figure 1B; Table 1). Overall,
the two families presented with a phenotype of ID, speech
delay, and microcephaly segregating in an autosomal-
recessive inheritance pattern (Figure 1A; Table 1; see Sup-
plemental Note).
Exome sequencing was performed on DNA from one
affected individual from each family at Radboudumc, Nij-
megen, the Netherlands6 and at the Institute of Human
Genetics, Erlangen, Germany.9 Among R15 variants that
passed our initial filtration criteria (see Riazuddin et al.6
and Reuter et al.9 for complete description), Sanger
sequencing revealed segregation of two novel bi-allelic
2-bp deletions, c.344_345delGA and c.571_572delAA, in
METTL5 (GenBank: NM_014168.2) with the ID phenotype
in families PKMR43M and F47949, respectively
(Figure 1A). Both variants are predicted to disrupt the
reading frame and cause premature truncation
(p.Arg115Asnfs*19; p.Lys191Valfs*10) of the encoded
METTL5 protein.
METTL5 is a functionally uncharacterized member of
the methyltransferase superfamily, which encompasses
33 METTL proteins with a seven-beta-strand methyltrans-
ferase domain. By homology with other family members,
it is predicted that METTL5 contains an S-adenosyl-L-
methionine-dependent DNA methyltransferase domain
and a DNA methylase N6 adenine-specific conserved site.
In the event that the mRNA harboring c.344_345delGA
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escapes the predicted non-mediated decay15 in vivo, the re-
sulting protein will lack the fully functional S-adenosyl-L-
methionine-dependent methyltransferase domain and
DNA methylase N6 adenine-specific site, whereas the
different predicted domains will remain conserved in
METTL5L191Vfs*10 (Figure 2A).
We analyzed the expression profile of METTL5 in the
developing and adult human brain (8 pcw to 40 years
old), from the RNA-seq data available in the Allen Brain
Atlas (see Web Resources). METTL5 is expressed from
very early development (8 pcw) and expression persists
through adulthood in multiple sub-structures of the hu-
man brain, including the cerebellar cortex, hippocampus,
and striatum (Table S1). To characterize the cellular local-
ization of METTL5, we used commercially available poly-
clonal antibody (NBP1-56640, RRID: AB_11039697,
Table 1. Clinical Findings of Affected Individuals from Families PKMR43M and F47949
Family 1, PKMR43M Family 2, F47949 Family from Hu et al.11
c.344_345delGA (p.Arg115Asnfs*19) c.571_572delAA (p.Lys191Valfs*10) c.182G>A (p.Gly61Asp)
Individual II:1 II:2 II:3 III:3 III:2 III:3 III:5
Gender female male male male male male female
Age at
evaluation
16 years 14 years 31 years 7 years 12 years 10 years 5 years
Congenital
anomalies
no no no fetal tachycardia,
hydrops fetalis
ASDII, pulmonic
stenosis
not reported not reported
General Features
Mental
retardation
severe severe severe severe moderate to severe severe severe
Speech delay yes yes yes yes, no speech yes, 4–5 word
sentences
slurred speech not reported
Weight 32 kg (4.9 SD) 50 kg (0.1 SD) 89 kg (1.9 SD) 16 kg (3.5 SD) 26 kg (2.8 SD) N/A N/A
Height 152 cm (1.6 SD) 157 cm (0.8 SD) 157 cm (2.7 SD) 114 cm (2 SD) 135 cm (2.3 SD) 133 cm (25%ile) 95 cm (3%ile)
Head
circumference
51 cm (3.1 SD) 48 cm (4.2 SD) 51 cm (2.8 SD) 46 cm (5 SD) 48 cm (4.7 SD) 46 cm (7 SD) 44 cm(8 SD)
Head Size microcephaly microcephaly microcephaly microcephaly microcephaly microcephaly microcephaly
Hypotonia no mild no no no N/A N/A
Epilepsy no no no no no no seizure
Spasticity no no no yes yes N/A N/A
Behavioral
problem
ADHD ADHD, aggressive ADHD, aggressive hand biting,
autistic
hand biting,
autistic
short temper,
aggressive
short temper,
aggressive
Eyes
Abnormalities no no no no no strabismus strabismus
Nose
Nose shape
anomalies
no broad nasal base,
over hanging
nasal tip
over hanging
nasal tip
large nose with
broad tip
large nose with
broad tip
narrow nasal
base, broad
nasal ridge
narrow nasal
base, broad
nasal ridge
Mouth
Dental
anomalies
no no dysplastic teeth no no N/A N/A
Shape
anomalies
no no no no no long philtrum
and thin
upper lip
long philtrum
and thin
upper lip
Ear
Ear shape
anomalies
large no large low-set and
posteriorly rotated
low-set and
posteriorly rotated
large no
Hearing loss no no no no no not reported not reported
Vestibular deficit no no no no no unbalanced gait no
ASDII, atrial septal defect type II; ADHD, attention-deficit/hyperactivity disorder
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Novus Biologicals) (Figure S2) and performed immuno-
staining and confocal imaging on postnatal (P) day
30 mouse brain. Similar to humans, we found low but
ubiquitous expression in the mouse brain (Figure S3). Im-
munolabeling of cultured rat hippocampal neurons
showed an enrichment of METTL5 in the soma and the
nucleus as well as in the pre- and post-synaptic regions
(Figure 2D). Taken together with the domain structures,
these data suggest that METTL5 might have a global epige-
netic regulatory role in the brain as well as a synapse-
dependent role. Several publications highlighted the
importance of synapse-autonomous regulatory mecha-
nisms,17,18 including regulation involving METTL pro-
teins.19
To evaluate the functional impact of the ID-associated
variants on METTL5 protein structure and function, we
first performed molecular modeling using PHYRE216 and
Chimera20 programs (Figure 2C). As anticipated, both
frameshift variants (c.344_345delGA and c.571_572delAA)
are predicted to have significant impact on the protein sec-
ondary structure and remove the evolutionary conserved
two a helix and/or b sheets from the C-terminal region.
To functionally validate the in silico predictions, we next
investigated the impact of the variants on the stability
and/or targeting of METTL5 in heterologous cells. We
included in our study another candidate missense variant
(c.182G>A [p.Gly61Asp]) (Figures 2A and 2B) that has
been recently reported in an Iranian family with two
affected individuals. While clinical features were similar
to the phenotypes (Table 1) found in our two families,
including severe ID, microcephaly, short temper, aggres-
sive behavior, and various facial dysmorphisms,11 no
Figure 2. Frameshift Variants in METTL5
Impact the Predicted Domains and
Conformation of the Protein, Ubiquitously
Expressed in the Brain
(A) Alternative splicing leads to three
isoforms of human METTL5. Non-coding
segments and coding regions of exons
are denoted by gray and black boxes,
respectively. Regions coding for the S-ad-
enosyl-L-methionine-dependent-methyl-
transferase domain are colored in orange.
Variants analyzed in this study are depicted
in red (PKMR43M), purple (F47949), and
blue.11 The numbering of the position
of variants c.182G>A (p.Gly61Asp),
c.344_345delGA (p.Arg115Asnfs*19), and
c.571_572delAA (p.Lys191Valfs*10) is
based on accession number GenBank:
NM_014167.2. The three isoforms lead to
a unique protein, predicted to contain
an S-adenosyl-L-methionine-dependent-
methyltransferase (orange, amino acids
12–161), amethyltransferase small domain
(brown box, amino acids 46–146), S-ad-
enosylmethionine binding sites (dark
brown box, amino acids 58L, 59G, 60C,
61G, 62C, 63G, 64V, 81D, 82I, 107C,
108D, 109V, 126V), and a DNA-methylase
n-6-adenine-specific conserved site (red
box, amino acids 123–129). The localiza-
tion of the peptide used to produce the
METTL5 antibody described in the
following analysis is shown as a green bar
(Novus Biologicals Cat# NBP1-56640,
RRID:AB_11039697, amino acids 35–83).
(B) Protein modeling of the WT and the
two novel mutant proteins, using PHYRE2
software,16 shows that the overall confor-
mation of the protein is not affected by
the different disease-causing variants.
However, due to early termination codon,
2 a helix and 2 b sheet are missing in
METTL5R115Nfs*19 and 2 b sheet are missing
in METTL5L191Vfs*10. The red and purple arrows represent the site of truncation in variant p.Arg115Asnfs*19 and p.Lys191Valfs*10,
respectively, and the blue arrow highlights the amino acid at position 61. Cyan, N terminus of the protein; yellow, C terminus of the
protein.
(C) Representative immunofluorescent labeling images of endogenous METTL5 (green) highlight the partial co-localization of the WT
protein with pre-synaptic (Bassoon, Enzo Life Sciences Cat# SAP7F407, RRID:AB_2313990, red) and post-synaptic (PSD95, UC Davis/
NIH NeuroMab Facility Cat# 75-028, RRID:AB_2292909, red) markers in rat hippocampal neurons in culture. All images are projection
of confocal optical sections stack. Scale bars: 10 mm.
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functional studies were performed to determine the patho-
genicity of the p.Gly61Asp variant on the encoded
METTL5.
For these studies, full-length METTL5 was amplified
from a human liver tissue cDNA library (TakaraBio) and
was inserted in pCMV-Myc and peGFP-C2 vectors
(TakaraBio). The constructs harboring ID-associated vari-
ants (METTL5G61D; METTL5R115Nfs*19; METTL5L191Vfs*10)
were prepared through site-directed mutagenesis (Agilent
Technologies) using the wild-type construct (METTL5WT)
as a template. All constructs sequences were validated by
Sanger sequencing (primers sequences are available upon
request). When transiently expressed in COS7 cells, both
Myc- and GFP-tagged METTL5WT as well as mutant pro-
teins were found in the cytoplasm and in slightly higher
amounts in the nucleus (Figures 3A and S4A). Similarly,
when transfected in cultured rat hippocampal neurons,
wild-type and mutant METTL5-GFP tagged proteins were
observed in the nucleus, as well as in the neuronal den-
drites (Figure S5).
In COS7 cells, no apparent difference in the levels and
localization of METTL5G61D protein was observed, when
compared with wild-type METTL5 (Figure 3B). In contrast,
the levels of METTL5R115Nfs*19 and METTL5L191Vfs*10 were
significantly reduced as compared to wild-type METTL5
(Figure 3B). Western blot analyses using transiently trans-
fected HEK293T cells further confirmed that both trun-
cating variants significantly (**p < 0.01, ***p < 0.001)
affected the stability of the mutant METTL5 protein (Fig-
ures 3C, 3D, and S4). To determine whether the observed
decrease in protein expression is due to protein instability,
we challenged the stability of Myc-tagged proteins. At 48 h
post transfection, cells were treated for 4 h with either
MG132 (50 mM, proteasome inhibitor, Sigma-Aldrich) or
CHX (cyclohexamide, 0.1 mM, synthesis blocker, Sigma-
Aldrich). Post-MG132-treatment western blot analysis
revealed a dramatic increase in the levels of truncated pro-
teins while post-CHX treatment did not highlight any
remarkable difference between the WT and the mutant
proteins, which suggest that c.344_345delGA and
c.571_572delAA variants significantly reduce the stability
of the corresponding proteins (Figure 3E).
We next investigated the function ofMettl5 in the devel-
oping brain and neurons in zebrafish, which express the
orthologous mettl5 gene (GenBank: NM_001005949.1)
throughout development (Figure 4A).22 Using specific
translation blocking morpholino (MO) (50-GCTCTCCAGC
TCTTTCAGCTTCATT-30; 2 ng) and splice site (exon 3) tar-
geting MO (50-GGTTAGTGAGTTTTCTTACCCTGGT-30;
5 ng), we knocked down mettl5 in embryos of NeuroD-
eGFP transgenic zebrafish strain.23 At 72 h post-fertiliza-
tion (hpf) mettl5 morphants had reduced head size,
mimicking the human microcephaly, and curved tails,
while the control morpholino (50- CCTCTTACCTCAGTTA
CAATTTATA-30)-injected embryos had normal growth (Fig-
ures 4B, 4C, and S6). To rule out MO toxicity, we used
various dilutions and also blocked the p53 pathway via
co-injection of a p53-targeting MO.24 The phenotype of
the co-injected embryos was identical to that of those in-
jected with the Mettl5 ATG blocker or splice-targeting
MO alone. Thus, morphant developmental deficits appear
to be specific to the knockdown ofmettl5 expression. Next,
we further examined the brain structure in mettl5 mor-
phants and controls embryos. Although no statistically sig-
nificant difference in hindbrain size was observed, both
the forebrain and the midbrain were adversely altered
with a 24%–26% and 16%–23% size reduction, respec-
tively (p < 0.0001), which further confirms the essential
role of mettl5 in brain development.
Even though the precise function ofMETTL5 is currently
uncharacterized, our study highlights its essential role in
human and zebrafish brain development and cognitive
function. In this study, we have identified two bi-allelic
frameshift variants: c.344_345delGA and c.571_572delAA.
Despite a low pLI score for METTL5 (pLi ¼ 0), no loss-of-
function variants in a homozygous state was found in
the gnomAD database, indicating the in-tolerance to bi-al-
lelic truncating variants. Our functional analyses revealed
that both c.344_345delGA and c.571_572delAA variants
drastically impact the expression and the conformation
of the protein (Figures 2 and3), and thus taken together
with the genetic and in silico analysis, both these variants
can be classified as ‘‘pathogenic’’ according to the
ACMG/AMP guidelines25 (Table S2). The candidate
missense variant p.Gly61Asp reported previously,11 replac-
ing highly evolutionary conserved amino acid (Figure S7),
is predicted to be pathogenic by several in silico algorithms
(Table S3). However, our 3Dmodeling (Figure S7) as well as
expression and localization studies (Figure 3) failed to
demonstrate a functional impact on the encoded protein,
and thus classified here as ‘‘variant of uncertain signifi-
cance’’ (Table S2).
In humans, variants in METTL proteins have been asso-
ciated with various disorders, such as sclerosis (METTL126
[MIM: 404466]), liver cancer (METTL327 [MIM: 612472]),
breast cancer (METTL3,28 METTL629), colon cancer
(METTL8 [MIM: 609525] and METTL1630), pancreatic can-
cer (METTL1331 [MIM: 617987]), otoprotection/hearing
loss (MIM: 605429) (METTL1332), and osteoporosis
(METTL21C33 [MIM: 615259]). Furthermore, variants in
other methyltransferase-like genes associated with ID
have been reported previously.34–37 For instance, trun-
cating alleles of METTL23 (MIM: 615262) have been
identified in families with mild non-syndromic ARID or
cognitive dysfunction with mild dysmorphic features
(MIM: 615942). Similarly, micro-duplications (351 kb and
432 kb genomic region), both containing METTL4 among
other genes, were associated with ID and mild dysmorphic
features.36,37 In addition to these METTL proteins, various
methyltransferases, including histone methyltransferases
(EHMT138 [MIM: 607001], KMT2A39 [MIM: 159555]),
DNA methyltransferase (DNMT3A40 [MIM: 602769]),
tRNA (TRMT141 [MIM: 611669], NSUN242,43 [MIM:
610916]), and rRNA methyltransferases (FTSJ144 [MIM:
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300499]), have been implicated in ID, highlighting the
importance of methyltransferases in the brain develop-
ment and cognitive functions.
A growing body of evidence shows that methyltrans-
ferases and other epigenetic regulators play an important
role in neurodevelopment and/or neuroplasticity.45,46
The presence of putative DNA methylase N6 adenine-spe-
cific conserved site as well as the accumulation of METTL5
in the nucleus tend to suggest an important role of
METTL5 as an epigenetic regulator. In silico and homology
analyses predicted METTL5 interaction with DNA; how-
ever, there is only experimental evidence showing that it
interacts with RNA.47 N6-adenine RNA methylation has
been implicated in the regulation of gene expression,
translation efficiency, mRNA stability,48 as well as in
neuropsychiatric disorders,49 although the mechanism
and impact are not fully understood yet.50–52 Among
others, METTL3 and METTL14 (MIM: 616504) are of
particular interest as they belong to the METTL family
and form a complex which is important for N6-adenine
RNA methylation.53 A recent study, using Mettl14 trans-
genic mice, showed that Mettl14 regulates the size of the
brain and more particularly the size of the cerebral cortex,
via altered histone modifications.54 Knocking out Mettl14
specifically in the neural stem cells leads to micro-
cephaly.54 Similarly, the ablation of Mettl3 in mice leads
Figure 3. Disease-Causing Variants
Affect the Stability of METTL5
(A) Immunolabeling of Myc-METTL5
fusion proteins for WT and the three
variants associated with ID, after trans-
fection in COS7 cells. The subcellular
localization shows that METTL5 (green)
accumulates in the nucleus (blue) and
forms aggregates in the cytoplasm. The
two frameshift variants as well as the
missense variant do not seem to affect
this localization. All images are projection
of confocal optical sections stack. Scale
bar: 10 mm.
(B) Quantification of the signal intensity
for METTL5 in the nucleus in the
different conditions show that only the
truncating variants affect the level of
expression of the protein. COS7 cells
were co-transfected with peGFP empty
vector and the different pCMV-Myc-
METTL5 constructs. The intensity of the
METTL5 and GFP signals in the nucleus
were measured using ImageJ software
and averaged from five areas per nucleus.
METTL5 signal was normalized against
GFP signal, minimizing the effect of
transfection efficiency among cells and
experiments (one-way ANOVA analysis
followed by a Bonferroni post hoc test,
****p < 0.0001).
(C and D) Western blot on transfected
HEK293T cells with Myc-METTL5 WT or
mutant constructs reveals that both
frameshift variants decrease the stability
of the mutant proteins, but the missense
variant does not.
(C) Representative image of western blot
assay. An antibody against Myc (Covance
Research Products Inc., Cat# MMS-164P-
100, RRID:AB_291335) was used to
analyze Myc-METTL5 signal. GFP signal
was used as a transfection control.
(D) Quantification of the signal intensity
for Myc and GFP was measured using
ImageJ software. Myc signal intensity
was normalized against the GFP signal intensity (one-way ANOVA analysis followed by a Bonferroni post hoc test, **p < 0.01,
****p < 0.0001).
(E) Representative image of western blot assay. 48 h after transfection, cells were collected (t ¼ 0) to assess initial expression level of
the protein. Remaining cells were treated either with vehicle (0.5% DMSO), MG132 (50 mM), or cyclohexamide (CHX, 0.1 mM) for
4 h. Mutant METTL5 bands intensity increases drastically after treatment with MG132, while the cyclohexamide treatment does not
alter differently WT and mutant proteins, suggesting that the disease-causing variants affect the stability of the protein rather than
the mRNAs.
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to developmental defects associated with depletion of m6A
and dramatic change in the expression of apoptosis and
cerebellum development-related genes.55 In addition to
their roles in the regulation of brain development, both
Mettl3 and Mettl14 are key molecules that can alter
learning abilities.56,57 METTL3-METTL14 complex is one
of the main components, but it does not account for all
the N6-methyladenosine (m6A) modifications. The identi-
fication of METTL16, another methyltransferase-like pro-
tein, as a new m6A methyltransferase58 suggests that other
methyltransferase-like family members like METTL5 may
also carry m6A methyltransferase activity.
In summary,METTL5 variants underlie autosomal-reces-
sive IDwithmicrocephaly inhumans.METTL5 is expressed
in the developing and aging brain, accumulates in the nu-
cleus and the synapses of neurons, and shares several do-
mains structure with other m6A modifiers. Therefore, we
speculate that human METTL5 participates in the epige-
netic regulation of DNA/RNA in the neurons. Our studies
reveal that, as in humans, zebrafish Mettl5 is critical for
proper brain development and possibly neuronal function.
Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
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